# ENCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/encell

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.encellinc.com
- Total disclosed funding: $32M
- Latest round: Series B (Jun 4, 2021)
- Investors on record: 9

## About

Founded in 2018 and based in Seoul, South Korea, ENCell is a stem cell company that specializes in the development of rare disease drugs using stem cells. In December 2025, ENCell raised KRW 22.5 billion in PIPE funding led by NH Investment & Securities, with participation from Meritz Securities, BNH Investment, Partners Investment, and Samsung Securities. Jang Jong-wook is the founder and CEO of the company.

The company offers services including consignment production of advanced biopharmaceuticals (CMO), advanced biopharmaceutical consignment development (CDO), and microbial verification service. media and water for injection verification services, residue verification services, cell characteristics analysis verification services, and manufacturing environment verification services.

The firm provides GMP facilities and operates for cell and gene therapy and provides customized services for the entire drug development cycle, from initial development to product approval at the request of customers. ENCell also improves the quality of life of patients and provides fundamental treatment of rare and incurable diseases through the development of stem cell processes and the development of next-generation stem cell drugs for rare and incurable diseases. 

In 2021, the startup generated revenue of KRW 3900 million. The company plans to use the December 2025 funds to commercialize its treatment EN001, support research and development, and expand its new anti-aging product line.

## Funding rounds

- Series B, Jun 4, 2021, $23M — Samsung Venture Investment, Smilegate Investment, Kolon Investment, DT&Investment, K2 Investment Partners, Evergreen Investment Partners, Won & Partners, T Investment, GU Equity Partners
- Series A, Feb 14, 2020, $8.5M — Samsung Venture Investment, Smilegate Investment, Kolon Investment, DT&Investment, Evergreen Investment Partners, Won & Partners, T Investment, GU Equity Partners

## Investors

- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series A, Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A, Series B
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A, Series B
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series A, Series B
- Evergreen Investment Partners (https://capitalatlas.ai/funds/evergreen-investment-partners) — Series A, Series B
- Won & Partners — Series A, Series B
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series A, Series B
- GU Equity Partners (https://capitalatlas.ai/funds/gu-equity-partners) — Series A, Series B
- K2 Investment Partners (https://capitalatlas.ai/funds/k2-investment-partners) — Series B